💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Abrocitinib

CHEMBL3655081 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
323.4 g/mol
LogP
1.7
Phase
4

Signalling inside the immune cell, rather than a surface receptor, is the point of intervention for abrocitinib, an oral inhibitor of Janus kinase 1. Interrupting JAK1 reduces transmission of the inflammatory cytokine signals responsible for itch and skin inflammation in eczema. Approval covers moderate-to-severe atopic dermatitis in adults and adolescents whose response to other treatments has been inadequate. The class carries defined safety considerations: live vaccines are avoided during treatment, and a small increase in the risk of serious infection, thrombosis and cardiovascular events is recognised. The molecule is a small molecule with formula C14H21N5O2S and a mass near 323.4 g/mol.

An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.

Peso molecular

323,4200 g/mol

LogP

1,70

TPSA

99,40 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Dermatitis atópica Dermatología Inmunología

Mecanismo de acción

A selective Janus kinase 1 (JAK1) inhibitor. Abrocitinib reversibly occupies the ATP-binding site of JAK1, interrupting JAK-STAT signal transduction by the cytokines that drive type 2 skin inflammation and itch, including interleukin-4, interleukin-13, interleukin-31 and interferon-gamma.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

A selective Janus kinase 1 (JAK1) inhibitor. Abrocitinib reversibly occupies the ATP-binding site of JAK1, interrupting JAK-STAT signal transduction by the cytokines that drive type 2 skin inflammation and itch, …

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H21N5O2S

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
Enlaces Rotables

                        
6

                    

                    
                    
                    

                        
Átomos Pesados

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.

                        

                    

                    

                    

                    
                    

                        
                        

                            
A selective Janus kinase 1 (JAK1) inhibitor. Abrocitinib reversibly occupies the ATP-binding site of JAK1, interrupting JAK-STAT signal transduction by the cytokines that drive type 2 skin inflammation and itch, including interleukin-4, interleukin-13, interleukin-31 and interferon-gamma.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Abrocitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3655081.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 78323835.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.